Bio

Dr. Setty is Surgical Director of the Cardiac Intensive Care Unit, Director of Global Cardiac Care, and a member of the pediatric cardiac surgery team. Dr. Setty completed his general surgery residency at Oregon Health Sciences University and spent an infolded year during his training at Green Lane Hospital in New Zealand as a research and pediatric/ adult cardiac surgery fellow. He then spent 3 years at the University of Minnesota/ Lillehei Heart Institute, the birthplace of cardiac surgery, completing his cardiothoracic surgery training. He performed his congenital heart surgery fellowship at the Royal Children’s Hospital in Melbourne, Australia. Dr. Setty is triple-board-certified in surgery, thoracic surgery, & congenital heart surgery. He has past experience in all aspects of pediatric and adult congenital cardiac surgery including neonatal and transplant surgery. He is a member of the medical school honor society, Alpha Omega Alpha. Dr. Setty also has numerous peer-reviewed publications, book chapters, and research presentations to his credit.
His current research focus includes: cardiac surgery outcomes with genetic syndromes, social determinants of health and its effect on cardiac surgery outcomes, big data in international cardiac surgery humanitarian centers, and the epigenetic delineation of congenital heart disease.

Clinical Focus

  • Thoracic and Cardiac Surgery

Academic Appointments

Professional Education

  • Board Certification: American Board of Thoracic Surgery, Congenital Cardiac Surgery (2011)
  • Board Certification: American Board of Thoracic Surgery, Thoracic and Cardiac Surgery (2007)
  • Fellowship: Royal Childrens' Hospital Pediatric Cardiac Surgery (2007) Australia
  • Fellowship: University of Minnesota Dept of Cardiothoracic Surgery (2006) MN
  • Board Certification: American Board of Surgery, General Surgery (2004)
  • Residency: Oregon Health and Science University General Surgery Residency (2003) OR
  • Medical Education: Medical College of Ohio (1997) OH

Contact

  • Academic
    spsetty@stanford.edu
    University - Academic staff Department: Cardiothoracic Surgery - Pediatric Cardiac Surgery Position: Clinical Assistant Professor
  • Clinical (Primary)  Pediatric Cardiac Surgery 300 Pasteur Dr CVRB Falk Bldg Stanford, CA 94305 (650) 725-0707 (fax)

Additional Clinical Info

Additional Info

All Publications

  • Free surgery for CHD through philanthropy-a sustainable model? INDIAN JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY Murthy, P., Jandhyala, S., Setty, S., Chodagam, S. 2024

    View details for DOI 10.1007/s12055-024-01813-7

    View details for Web of Science ID 001338053700001

  • Insights and perspectives into clinical biomarker discovery in pediatric heart failure and congenital heart disease-a narrative review CARDIOVASCULAR DIAGNOSIS AND THERAPY Liem, D. A., Cadeiras, M., Setty, S. P. 2023; 13 (1): 83-99

    Abstract

    Heart failure (HF) in the pediatric population is a multi-factorial process with a wide spectrum of etiologies and clinical manifestations, that are distinct from the adult HF population, with congenital heart disease (CHD) as the most common cause. CHD has high morbidity/mortality with nearly 60% developing HF during the first 12 months of life. Hence, early discovery and diagnosis of CHD in neonates is pivotal. Plasma B-type natriuretic peptide (BNP) is an increasingly popular clinical marker in pediatric HF, however, in contrast to adult HF, it is not yet included in pediatric HF guidelines and there is no standardized reference cut-off value. We explore the current trends and prospects of biomarkers in pediatric HF, including CHD that can aid in diagnosis and management.As a narrative review, we will analyze biomarkers with respect to diagnosis and monitoring in specific anatomical types of CHD in the pediatric population considering all English PubMed publications till June 2022.We present a concise description of our own experience in applying plasma BNP as a clinical biomarker in pediatric HF and CHD (tetralogy of fallot vs. ventricular septal defect) in the context of surgical correction, as well as untargeted metabolomics analyses. In the current age of Information Technology and large data sets we also explored new biomarker discovery using Text Mining of 33M manuscripts currently on PubMed.(Multi) Omics studies from patient samples as well as Data Mining can be considered for the discovery of potential pediatric HF biomarkers useful in clinical care. Future research should focus on validation and defining evidence-based value limits and reference ranges for specific indications using the most up-to-date assays in parallel to commonly used studies.

    View details for DOI 10.21037/cdt-22-386

    View details for Web of Science ID 000916653500001

    View details for PubMedID 36864972

    View details for PubMedCentralID PMC9971290

  • Postoperative and long-term outcomes in children with Trisomy 21 and single ventricle palliation CONGENITAL HEART DISEASE Peterson, J. K., Setty, S. P., Knight, J. H., Thomas, A. S., Moller, J. H., Kochilas, L. K. 2019; 14 (5): 854-863

    Abstract

    Patients with Trisomy 21 (T21) and single ventricle (SV) physiology present unique challenges compared to euploidic counterparts. This study reports postoperative and long-term outcomes in patients with T21 and SV palliation.This retrospective cohort study from the Pediatric Cardiac Care Consortium (PCCC) included patients with T21 (<21 years old) that underwent surgical palliation for SV between 1982 and 2008 and control patients without known genetic anomaly following Fontan palliation for similar diagnoses. Kaplan-Meier survival plots were created based on death events obtained from the PCCC and by linkage with the National Death Index (NDI) and the Organ Procurement and Transplantation Network (OPTN) through 2014 for patients with adequate identifiers.We identified 118 children with T21 who underwent initial surgical SV palliation. Among 90 (75.6%) patients surviving their first surgery, 66 (73.3%) underwent Glenn anastomosis and 25 (27.8%) completed Fontan palliation with in-hospital survival of 80.3% and 76.0%, respectively. Fifty-three patients had sufficient identifiers for PCCC-NDI-OPTN linkage. Ten-year survival, conditioned on discharge alive after the Fontan procedure, was 66.7% compared to 92.2% for 51 controls without genetic anomaly (P = .001). Median age at death for T21 patients following initial surgical SV palliation was 2.69 years (IQR 1.34-7.12) with most deaths (89.2%) attributed to the underlying congenital heart disease (CHD).Children with T21 and SV are at high risk for procedural and long-term mortality related to their genetic condition and underlying CHD. Nevertheless, a select group of patients can successfully complete Glenn or Fontan palliation, reaching satisfactory long-term survival.

    View details for DOI 10.1111/chd.12823

    View details for Web of Science ID 000477411300001

    View details for PubMedID 31332952

    View details for PubMedCentralID PMC7329297

https://orcid.org/0000-0001-7438-7402